CELCUITY INC (CELC) Stock Price, Quote, News and Overview
NASDAQ:CELC - Nasdaq - US15102K1007 - Common Stock - Currency: USD
CELC Quote, Performance and Key Statistics
13.15
+0.02 (+0.15%)
The current stock price of CELC is 13.15 USD. In the past month the price increased by 12.78%. In the past year, price decreased by -14.28%.
CELC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CELC
Company Profile
Celcuity, Inc. is cellular analysis company. The company is headquartered in Minneapolis, Minnesota and currently employs 55 full-time employees. The company went IPO on 2017-09-20. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.
Company Info
CELCUITY INC
16305 36th Ave N Ste 100
Minneapolis MINNESOTA 55446 US
CEO: Brian F. Sullivan
Employees: 55
Company Website: https://www.celcuity.com/
Investor Relations: https://celcuity.com/home/investors/sec-filings/
Phone: 17633920767
CELCUITY INC / CELC FAQ
What is the stock price of CELCUITY INC today?
The current stock price of CELC is 13.15 USD. The price increased by 0.15% in the last trading session.
What is the ticker symbol for CELCUITY INC stock?
The exchange symbol of CELCUITY INC is CELC and it is listed on the Nasdaq exchange.
On which exchange is CELC stock listed?
CELC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CELCUITY INC stock?
14 analysts have analysed CELC and the average price target is 31.62 USD. This implies a price increase of 140.46% is expected in the next year compared to the current price of 13.15. Check the CELCUITY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CELCUITY INC worth?
CELCUITY INC (CELC) has a market capitalization of 488.26M USD. This makes CELC a Small Cap stock.
How many employees does CELCUITY INC have?
CELCUITY INC (CELC) currently has 55 employees.
What are the support and resistance levels for CELCUITY INC (CELC) stock?
CELCUITY INC (CELC) has a support level at 12.8 and a resistance level at 13.15. Check the full technical report for a detailed analysis of CELC support and resistance levels.
Should I buy CELCUITY INC (CELC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CELC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CELC, evaluating the profitability, health, valuation and growth aspects
- CELCUITY INC (CELC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CELCUITY INC (CELC) Sales and EPS estimates to see what analysts future expectations are.
- CELCUITY INC (CELC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CELCUITY INC (CELC) Insider and Institutional Ownership to learn about the owners and their transactions.
- CELCUITY INC (CELC) Stock Chart to make your own analysis
- CELCUITY INC (CELC) Latest news and press-releases to stay up to date.
Does CELCUITY INC (CELC) stock pay dividends?
CELC does not pay a dividend.
When does CELCUITY INC (CELC) report earnings?
CELCUITY INC (CELC) will report earnings on 2025-03-20, after the market close.
What is the Price/Earnings (PE) ratio of CELCUITY INC (CELC)?
CELCUITY INC (CELC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.61).
What is the Short Interest ratio of CELCUITY INC (CELC) stock?
The outstanding short interest for CELCUITY INC (CELC) is 11.12% of its float. Check the ownership tab for more information on the CELC short interest.
CELC Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to CELC. When comparing the yearly performance of all stocks, CELC is a bad performer in the overall market: 74.13% of all stocks are doing better.
CELC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CELC. CELC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CELC Financial Highlights
Over the last trailing twelve months CELC reported a non-GAAP Earnings per Share(EPS) of -2.61. The EPS increased by 4.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.42% | ||
| ROE | -62.77% | ||
| Debt/Equity | 0.65 |
CELC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to CELC. The Buy consensus is the average rating of analysts ratings from 14 analysts.